Goldman Sachs Reinstates 4D Molecular Therapeutics (FDMT) at Buy, 'Platform value to inflect via 2024 catalysts'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
4D Molecular Therapeutics Inc. (FDMT) Files Mixed Shelf
February 5, 2024 4:38 PM EST4D Molecular Therapeutics Inc. (NASDAQ: FDMT) has filed mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
... More4D Molecular Therapeutics Inc. (FDMT) Files Mixed Shelf
February 5, 2024 4:38 PM EST4D Molecular Therapeutics Inc. (NASDAQ: FDMT) has filed mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
... More4D Molecular Therapeutics (FDMT) Announces $250M Share Offering
February 5, 2024 4:05 PM EST4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. 4D Molecular Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock offered in the proposed offering. All of the shares in the proposed offering are to be sold by 4D Molecular Therapeutics. The offering is subject... More
4D Molecular Therapeutics (FDMT) PT Raised to $70 at BMO Capital, 'Strong PhII Data Support Our Top-Pick Thesis'
February 5, 2024 1:03 PM EST(Updated - February 5, 2024 1:04 PM EST)
BMO Capital analyst Kostas Biliouris raised the price target on 4D Molecular Therapeutics (NASDAQ: FDMT) to $70.00 (from $50.00) while maintaining a Outperform rating.
The analyst comments "The 4D-150 PhII results met investor expectations outlined here,... More
4D Molecular Therapeutics (FDMT) PT Raised to $38 at Chardan, 'Phase II wAMD Data Set Up a Competitive GT Profile'
February 5, 2024 10:12 AM EST(Updated - February 5, 2024 10:14 AM EST)
Chardan Capital Markets analyst Geulah Livshits raised the price target on 4D Molecular Therapeutics (NASDAQ: FDMT) to $38.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "On 3 February, 4D Molecular Therapeutics presented 24-week data from the phase II... More
4D Molecular Therapeutics (FDMT) PT Raised to $35 at RBC Capital
February 5, 2024 8:29 AM ESTRBC Capital analyst Lisa Walter raised the price target on 4D Molecular Therapeutics (NASDAQ: FDMT) to $35.00 (from $25.00) while maintaining a Outperform rating.... More
4D Molecular Therapeutics (FDMT) Climbs 40% Following Positive Data from Phase 2 Trial of Intravitreal 4D-150
February 5, 2024 7:09 AM EST4D Molecular Therapeutics (NASDAQ: FDMT) Climbs 40% Following Positive Data from Phase 2 Trial of Intravitreal 4D-150
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in... More